Nucala

Active Ingredient(s): Mepolizumab
FDA Approved: * November 4, 2015
Pharm Company: * GLAXOSMITHKLINE LLC
Category: Asthma

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nucala Overview

Mepolizumab (trade name Nucala) is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma. It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system. Contents 1 Medical uses 2 Side effects 3 Overdose 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 8 Research 9 References Medical uses Mepolizumab is approved by the U.S. Food and Drug Administration (FDA) for the maintenance...

Read more Nucala Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mepolizumab

Recent Nucala Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Nucala: (3 results)

Sorted by National Drug Code

• 0173-0881 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline LLC
• 0173-0892 Nucala 100 mg/ml Subcutaneous Injection, Solution by Glaxosmithkline LLC
• 12064-018 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa

Other drugs which contain Mepolizumab or a similar ingredient: (1 result)

• MEPOLIZUMAB 2 discussions